Further subgroup analysis restricted to patients with HER2‐negative tumors showed similar results (log‐rank p = .002), with 20‐year survival proportions by DRFI of 59% (95% CI, 52%–68%) and 74% (95% CI, 69%–79%) for patients with high and low PR intra‐tumor heterogeneity, respectively (Figure 3B). Here, ERBB2 is linked to neoplasm.